ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Insulin glargine (Ondibta)

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

Biosimilar
CHMP opinion 13 Nov 2025 → EU licence 9 Jan 2026 · Sandoz GmbH

Research

Diabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-07-06

In 400 people aged 7–25 with type 1 diabetes in Bangladesh and Tanzania, switching to insulin glargine did not change time in very low glucose (3·6% vs 3·4%) or time in range (40·5% vs 38·1%) at 6 months versus usual isophane or premixed insulin.

RCTn = 400
Luo et al. Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial
Diabetes and endocrinology · Diabetes Care · 2026-02-01

Secondary analysis of GRADE (724 adults with type 2 diabetes on metformin): glucagon measures were not associated with HbA1c ≥7.0%, whereas a 1-SD rise in C-peptide index was associated with 17% lower risk; no clear drug differences on glucagon.

Secondary analysisn = 724
Kahn et al. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.